AQR Capital Management’s Dianthus Therapeutics DNTH Stock Holding History

AQR Capital Management’s Portfolio DNTH Stock Details DNTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$290K	Sell	2,974 -1,144	-28%	-$99.9K	﹤0.01%	3636
2026 Q1	$346K	Buy	+4,118	New	+$238K	﹤0.01%	3339
2022 Q2	–	Sell	-2,206	Closed	-$102K	–	2204
2022 Q1	$102K	Buy	2,206 +689	+45%	+$37.6K	﹤0.01%	2134
2021 Q4	$107K	Sell	1,517 -842	-36%	-$84.6K	﹤0.01%	2143
2021 Q3	$275K	Buy	+2,359	New	+$275K	﹤0.01%	2058
2021 Q1	–	Sell	-1,635	Closed	-$205K	–	2211
2020 Q4	$205K	Sell	1,635 -148	-8%	-$16.8K	﹤0.01%	2086
2020 Q3	$194K	Sell	1,783 -8	-0.4%	-$948	﹤0.01%	2066
2020 Q2	$215K	Buy	1,791 +1,094	+157%	+$154K	﹤0.01%	1977
2020 Q1	$70K	Buy	+697	New	+$129K	﹤0.01%	1993

Other funds holding DNTH

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

AQR Capital Management's DNTH Position: Q2 2026 in Review

AQR Capital Management reduced its Dianthus Therapeutics (DNTH) stake by 28% in Q2 2026, selling an estimated $99.9K and leaving 2,974 shares worth $290K. The position accounts for ﹤0.01% of the portfolio, ranked #3636.

AQR Capital Management first reported a position in DNTH in Q1 2020 and has held it in 9 quarters since. The position peaked at $346K in Q1 2026. 270 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

AQR Capital Management held 2,974 shares of Dianthus Therapeutics worth $290K as of Q2 2026.
AQR Capital Management sold 1,144 Dianthus Therapeutics shares in Q2 2026, an estimated $99.9K.
Dianthus Therapeutics made up ﹤0.01% of AQR Capital Management's portfolio in Q2 2026, its #3636 holding.
AQR Capital Management first reported a position in Dianthus Therapeutics in Q1 2020 and has held it in 9 quarters since.
AQR Capital Management's Dianthus Therapeutics position peaked at $346K in Q1 2026.
270 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.